CLDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Celldex Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$29.67+2.14 (+7.77%)
Close on Oct 19, 2026
- Market cap
- $2.31B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
87.1%−10.2 pts over 5 years
Operating margin
-18599.8%−17745.7 pts over 5 years
Net margin
-16748.0%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -78.0% | -13.1% | -26.9% | -11.9% | |
| Gross profit | -80.3% | -15.8% | -28.5% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | -40.6% | |
| Return on assets | – | – | -37.6% | |
| Current ratio | 5.55 | 13.93 | 10.49 | |
| Capex to revenue | 40.5% | 20.9% | 175.7% | |
| Diluted shares | 7M | 0M | 66M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Celldex Therapeutics generated $640.66M from operations and spent $9.53M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$640.66M
Used
$9.53M
Capital expenditure$9.53M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-16748.0%
×Asset turnover0.00×
×Equity multiplier1.08×
=Return on equity, FY2025-40.6%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -16748.0% | 0.00× | 1.08× | -40.6% |
| FY2024 | -2248.8% | 0.01× | 1.07× | -26.8% |
| FY2023 | -2054.8% | 0.02× | 1.08× | -37.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$258.76M
- Cash generatingOperating cash flow above zero-$210.95M
- Return on assets improvedROA up on the prior year-33.9% → -32.7%
- Earnings backed by cashOperating cash flow above net income-$210.95M vs -$258.76M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose18.91 → 10.49
- No dilutionShare count did not rise64M → 66M
- Gross margin improvedGross margin up on the prior year97.15% → 87.06%
- More efficientAsset turnover rose0.02 → 0.00